JNJ's Janssen unit gets Invega approval |
|
|
|
Published
:
Fri, 27 Apr 2007 20:30
|
NEW BRUNSWICK, N.J. (AP) - Diversified health-care products maker Johnson & Johnson on Friday said its Janssen LP unit received Food and Drug Administration additional approvals for its schizophrenia drug Invega.The drug was already approved for uses as a short-term treatment. The FDA decision adds an indication for use as a long-term treatment.Shares of JNJ fell 4 cents to $64.20 on the New York Stock Exchange in afternoon trading.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
|
Print this Story
J&J gets subpoenas over three drugs 